20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.

ABSTRACT: As a public health problem, prostate cancer engenders huge economic and life-quality burden. Developing effective chemopreventive regimens to alleviate the burden remains a major challenge. Androgen signaling is vital to the development and progression of prostate cancer. Targeting androgen signaling via blocking the production of the potent ligand dihydrotestosterone has been shown to decrease prostate cancer incidence. However, the potential of increasing the incidence of high-grade prostate cancers has been a concern. Mechanisms of disease progression after the intervention may include increased expression of androgen receptor (AR) in prostate tissue and expression of the constitutively active AR splice variants (AR-Vs) lacking the ligand-binding domain. Thus, novel agents targeting the

SUBMITTER: Cao B 

PROVIDER: S-EPMC3509250 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature